1. The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial
- Author
-
Amal Ahmed Mohamed, Ahmed Abdel Halim, Sahar Mohamed, Seham Mohamed Mahmoud, Eman Mohamed Bahgat Eldemiry, Rasha Sobh Mohamed, Mahmoud Maamoun Shaheen, Gina G. Naguib, Nashwa M. Muharram, Mona G. Khalil, Salma Saed, Randa Ibrahim, Ahmed Salah Seif, Noha Kamal, Karima Nasraldin, Ali Elsaid Abdelrahman, and Radwa El Borolossy
- Subjects
Pharmacology ,Pharmacology (medical) - Abstract
Background and Aim: Non-alcoholic fatty liver (NAFLD) is one of the most common progressive metabolic disorders worldwide. There are increasing scientific interests nowadays for the association between vitamin D status and Non-alcoholic fatty liver. Earlier studies have revealed that vitamin D deficiency is highly prevalent in Non-alcoholic fatty liver patients that contributes to poor outcomes. Hence, the present study aimed to assess the efficacy and safety of oral cholecalciferol on Non-alcoholic fatty liver patients.Subjects and Methods: This study was conducted on 140 patients that were randomized either to group 1 that received the standard conventional therapy in addition to placebo or group 2 that received the standard conventional therapy in addition to cholecalciferol during the 4 months study period.Results: At the end of the study group 2 revealed significant decrease (p < 0.05) in the mean serum level of TG, LDL-C, TC, hsCRP as compared to their baseline results and group 1 results. Additionally, a significant improvement in the serum levels of ALT (p = 0.001) was seen in group 2 at the end of the study when compared to group 1. Whereas group 1 did not show any change in these parameters when compared to group 2 and their baseline results.Conclusion: Cholecalciferol was shown to have beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients.Clinical Trial Registration:https://prsinfo.clinicaltrials.gov/prs-users-guide.html, identifier NCT05613192
- Published
- 2023
- Full Text
- View/download PDF